Jane Little, MD, awarded RO1 from NIH
Hypoxemia with Sleep in Sickle Cell Anemia-Prevalence, Clinical and Cellular Impact & Response to Therapy: A Multi-Site Prospective Study Accessing New Collaborative Pathways
Sickle cell disease (SCD) arises from a gain-of function mutation of hemoglobin (Hb) in which deoxygenated sickle hemoglobin (deoxy-HbS) polymerizes, resulting in rigid, adhesive, and fragile red blood cells (RBCs) which in turn cause anemia, inflammation, progressive vasculopathy and multiorgan failure. Decreased Hb oxygen saturation (SpO2), or ‘hypoxemia’, may exacerbate SCD due to the centrality of deoxy-HbS in disease pathophysiology.
We will examine the prevalence, impact, and response to treatment of hypoxemia during sleep in adults living with homozygous sickle cell anemia (SCA) at four comprehensive sickle cell centers across the U.S., focusing on patient reported outcomes (PROs), disease activity, cardiopulmonary health, and cellular biomarkers.
https://reporter.nih.gov/search/vZxbRn76DEqdiZLG4bMeHg/project-details/11244472